What is Zacks Research’s Estimate for PCRX FY2027 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Pacira BioSciences in a research report issued on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will post earnings per share of $2.45 for the year. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share.

A number of other research firms also recently weighed in on PCRX. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price target for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Barclays raised their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Needham & Company LLC raised their price target on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, HC Wainwright raised their price target on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $27.22.

Pacira BioSciences Stock Up 1.3 %

Shares of Pacira BioSciences stock opened at $24.14 on Monday. The business’s 50 day simple moving average is $24.44 and its 200 day simple moving average is $19.61. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $31.67. The firm has a market cap of $1.12 billion, a PE ratio of -11.89 and a beta of 0.86. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Hedge Funds Weigh In On Pacira BioSciences

A number of institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio raised its holdings in shares of Pacira BioSciences by 21,458.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 91,192 shares of the company’s stock worth $1,718,000 after buying an additional 90,769 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Pacira BioSciences by 26.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,855 shares of the company’s stock worth $1,975,000 after buying an additional 21,781 shares in the last quarter. Voloridge Investment Management LLC increased its holdings in Pacira BioSciences by 129.2% in the 4th quarter. Voloridge Investment Management LLC now owns 116,149 shares of the company’s stock worth $2,188,000 after purchasing an additional 65,467 shares in the last quarter. Squarepoint Ops LLC increased its holdings in Pacira BioSciences by 72.2% in the 4th quarter. Squarepoint Ops LLC now owns 60,836 shares of the company’s stock worth $1,146,000 after purchasing an additional 25,505 shares in the last quarter. Finally, Two Sigma Advisers LP acquired a new position in Pacira BioSciences in the 4th quarter worth about $797,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.